Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
1.
Artigo em Inglês | MEDLINE | ID: mdl-19171992

RESUMO

Cutaneous leishmaniasis is a disease caused by intracellular protozoal parasites belonging to the genus Leishmania. Immune suppression caused by HIV infection is an important factor for atypical presentation and widespread progression of cutaneous leishmaniasis. Diffuse (disseminated) cutaneous leishmaniasis and HIV co-infection is emerging as an extremely serious new disease. A 38-year-old HIV-positive man presented with a 12-month history of a progressive papule and nodular eruptions on face and extremities with infiltrations of nasal and oral mucosa. We report the case due to its atypical, widespread muco-cutaneous presentation masquerading as lepromatous leprosy.


Assuntos
Infecções por HIV/complicações , Infecções por HIV/diagnóstico , HIV , Leishmaniose Tegumentar Difusa/complicações , Leishmaniose Tegumentar Difusa/diagnóstico , Adulto , Infecções por HIV/tratamento farmacológico , Humanos , Cetoconazol/uso terapêutico , Leishmaniose Tegumentar Difusa/tratamento farmacológico , Masculino
3.
Eur J Pharm Biopharm ; 66(1): 95-105, 2007 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-17045468

RESUMO

The objectives of this investigation were to study the physico-chemical properties of hot-melt extruded (HME) films for onychomycosis and to determine the stability of the model antifungal drug incorporated within these films. The influence of etching and instrument variables on the bioadhesion of these drug delivery systems for the human nail was also studied. Six 250 g batches (F1-F6) of hydroxypropyl cellulose (HPC) and/or poly(ethylene oxide) films containing ketoconazole (20%) were extruded using a Killion extruder (Model KLB-100). The thermal properties of HME films were investigated using differential scanning calorimetry (DSC). Scanning electron microscopy (SEM) was used to examine the surface morphology of the films and X-ray diffraction (XRD) was used to investigate the crystalline properties of the drugs, physical mixtures as well as the HME films. Stability studies were performed on the films stored at 25 degrees C/60%RH. The bioadhesive properties of these films were investigated on the human nail (ex vivo) using a Texture Analyzer. The nail samples tested were either non-treated (control) or treated with an etching gel. The parameters measured were peak adhesion force (PAF) and area under the curve (AUC). The Hansen solubility parameter was calculated using a combination of Hoy and Hoftyzer/Van Krevelen methods to estimate the likelihood of drug-polymer miscibility. SEM provided direct physical evidence of the physical state of the drug within the films. The theoretical post-extrusion content of ketoconazole remaining in the six film batches ranged from 90.3% (+/-2.2) to 102.4% (+/-9.0) for up to 6 months and from 83.9% (+/-3.6) to 91.6% (+/-3.0) for up to 12 months. Bioadhesion studies of HPC film tested on 'etched' nails recorded significantly higher PAF and AUC than that of the non-treated 'control' nails. Ketoconazole was found to be relatively stable during the extrusion process. Melting points corresponding to the crystalline drugs were not observed in the processed films. The Hansen solubility parameters predicted miscibility between the polymers and the drug. The predictions of the solubility parameters were in agreement with DSC, XRD and SEM results. Bioadhesion measurements of the film on the human nail substrate were generally higher for the etched nails than that of the control nails.


Assuntos
Sistemas de Liberação de Medicamentos , Cetoconazol/uso terapêutico , Onicomicose/tratamento farmacológico , Adesividade , Administração Tópica , Antifúngicos/química , Antifúngicos/farmacocinética , Antifúngicos/uso terapêutico , Área Sob a Curva , Varredura Diferencial de Calorimetria , Celulose/análogos & derivados , Celulose/química , Cromatografia Líquida de Alta Pressão , Estabilidade de Medicamentos , Humanos , Cetoconazol/administração & dosagem , Cetoconazol/química , Microscopia Eletrônica de Varredura , Unhas/metabolismo , Unhas/patologia , Polietilenoglicóis/química , Solubilidade , Tecnologia Farmacêutica/instrumentação , Tecnologia Farmacêutica/métodos , Difração de Raios X
4.
Br J Ophthalmol ; 83(2): 173-6, 1999 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-10396193

RESUMO

AIM: To describe leprosy characteristics, ocular features, and type of organisms that produce infective corneal ulcers in leprosy patients. METHOD: The records of all leprosy patients admitted for treatment of corneal ulcers between 1992 and 1997 were reviewed. RESULTS: 63 leprosy patients, 53 males and 10 females, are described. 16 were tuberculoid and 47 lepromatous. 25 patients had completed multidrug therapy. 10 patients had face patches, eight had type I reaction, and 10 had type II reaction. 43 (68%) patients had hand deformities. In 54% of patients pain was absent as a presenting symptom. 19 patients gave a history of trauma. In 15 patients ulcers had also occurred on the other eye, five of them having occurred during the study period and the rest before 1992. Of the 68 eyes with corneal ulcers, 28 had madarosis, 34 had lagophthalmos, nine had ectropion, three had trichiasis, six had blocked nasolacrimal ducts, and 39 decreased corneal sensation. In 14 eyes, a previous lagophthalmos surgery had been done. 16 patients were blind at presentation. 32% of ulcers were located centrally. After treatment only 18% of the eyes showed visual improvement. Five types of fungus were cultured, two of them rare ocular pathogens. CONCLUSIONS: Corneal ulcers occur more in males and in the lepromatous group of patients. Decreased corneal sensation, lagophthalmos and hand deformity are closely associated. Indigenous treatment and late presentations were notable in many patients. Visual outcome is not good. There is increased risk of developing an ulcer in the other eye. Fungal corneal ulcers are not uncommon.


Assuntos
Úlcera da Córnea/microbiologia , Hanseníase Virchowiana/complicações , Hanseníase Tuberculoide/complicações , Adulto , Idoso , Anti-Infecciosos/uso terapêutico , Ciprofloxacina/uso terapêutico , Úlcera da Córnea/tratamento farmacológico , Feminino , Humanos , Cetoconazol/uso terapêutico , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Acuidade Visual/fisiologia
6.
Posit Aware ; 7(6): 16-8, 1996.
Artigo em Inglês | MEDLINE | ID: mdl-11363974

RESUMO

AIDS: Recent research on the effects of opportunistic infections (OIs) on HIV replication suggests that the OIs can actually increase HIV replication through the production of cytokines. Treatment options for thrush include antifungal treatments for early episodes and reserving fluconazole for patients with difficult to treat infections. Other studies show that prevention and treatment of Mycobacterium avium complex (MAC) increases survival rates. Drugs and dosages are described.^ieng


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/tratamento farmacológico , Antifúngicos/uso terapêutico , Azitromicina/uso terapêutico , Candidíase Bucal/tratamento farmacológico , Fluconazol/uso terapêutico , Infecção por Mycobacterium avium-intracellulare/prevenção & controle , Infecções Oportunistas Relacionadas com a AIDS/complicações , Infecções Oportunistas Relacionadas com a AIDS/mortalidade , Anfotericina B/uso terapêutico , Antibacterianos/uso terapêutico , Antituberculosos/uso terapêutico , Contagem de Linfócito CD4/efeitos dos fármacos , Candidíase Bucal/complicações , Claritromicina/uso terapêutico , Ensaios Clínicos como Assunto , Clofazimina/uso terapêutico , Clotrimazol/uso terapêutico , Estudos de Coortes , Interações Medicamentosas , Resistência Microbiana a Medicamentos , Quimioterapia Combinada , Flucitosina/uso terapêutico , Fator Estimulador de Colônias de Granulócitos e Macrófagos/uso terapêutico , Inibidores da Protease de HIV/uso terapêutico , Humanos , Itraconazol/uso terapêutico , Cetoconazol/uso terapêutico , Hansenostáticos/uso terapêutico , Infecção por Mycobacterium avium-intracellulare/tratamento farmacológico , Nistatina/uso terapêutico , Rifabutina/uso terapêutico , Análise de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA